NUEVAS ESTRATEGIAS FARMACOLÓGICAS Y SU MECANISMO DE ACCIÓN EN EL TRATAMIENTO DE LA TB PULMONAR

Abstract

Pulmonary TB (PTB), caused by the bacillus Mycobacterium tuberculosis (Mtb), is one of the most prevalent and deadly infectious diseases worldwide. With approximately a quarter of the global population affected, TB stands as one of the leading causes of mortality within the spectrum of infectious diseases. Given this reality, there is an urgent need to explore and analyze new strategies that offer hope in the fight against this disease. This article aims to provide an analytical review of emerging strategies in the treatment of TB. To achieve this objective, a comprehensive review methodology has been adopted, encompassing a wide range of recent bibliographic sources, including academic research and specialized literature. The purpose is to compile and synthesize the most significant and up-todate contributions in the field, thus providing a clear and current overview of advances in the fight against TB. The article is structured into key sections that cover an introduction to the basic concepts of PTB, examining the epidemiology and interaction between Mtb and the host immune response, focusing on the formation of granulomas. Additionally, the pharmacodynamics and conventional treatments are analyzed, along with a critical study on drug resistance. It concludes by highlighting the need for innovation and personalization in treatments to address drug resistance, offering a comprehensive view of the current challenges and solutions in the management of TB.